ozurdex Report issue

Small molecule Experimental
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).   NCATS

Chemistry

  • SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
  • InChIKey: UREBDLICKHMUKA-CXSFZGCWSA-N
  • Mol. Mass: 392.4611
  • ALogP: 1.9
  • ChEMBL Molecule:
    dexamethasone  
More Chemistry

Pharmacology

  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral, Topical
  • Pro Drug: No

Alternative names

ozurdex

Organizations (28)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (12)


 

Conjunctivitis, Allergic (approved 1962)

Conjunctivitis, Bacterial (approved 1962)

Corneal Injuries (approved 1962)

Iritis (approved 1962)

Keratitis (approved 1962)

Keratitis, Herpetic (approved 1962)

Multiple Myeloma (approved 2016)

Postoperative Nausea and Vomiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Rosacea (approved 1962)

Shock, Septic

Uveitis, Intermediate (approved 1962)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Cataract (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetic Retinopathy (Phase 2)

Epiretinal Membrane (Phase 4)

Macular Degeneration (Phase 2)

Macular Edema (Phase 4)

Melanoma (Phase 2)

Retinal Diseases (Phase 2)

Retinal Vein Occlusion (Phase 4)

Uveitis (Phase 4)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue